The Lymphoid Malignancies Pipeline

Below is a list of agents under investigation for the treatment of lymphoid malignancies. Information was gathered from, as well as the respective drug manufacturers. Unless otherwise stated, these agents are being investigated in the relapsed and/or refractory disease setting. For a comprehensive list of agents being evaluated for these conditions, please consult

Phosphatidylinositide 3 Kinase (PI3K) Inhibitors

Apilimod dimesylate: a PIKfyve inhibitor for non-Hodgkin lymphoma (NHL)

Bimiralisib: an oral selective dual PI3K/mTOR inhibitor in preclinical lymphoma models

Buparlisib: a small molecule orally-available PI3K inhibitor for diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and FL

Duvelisib: a PI3Kδ and PI3Kγ inhibitor for previously untreated CD20-positive follicular lymphoma (FL)

Kinase Inhibitors

BGB-3111: a Bruton tyrosine kinase (BTK) inhibitor for DLBCL

ONC201: an Akt/ERK inhibitor for the treatment of MCL and DLBCL

SNS-062: a BTK inhibitor for CLL, small lymphocytic lymphoma (SLL), MCL, DLBCL, and FL

Monoclonal Antibodies

AFM13: an anti-CD30 and anti-CD16A bispecific antibody for CD30-positive lymphomas

Cirmtuzumab: an anti-ROR1 monoclonal antibody for B-cell chronic lymphocytic leukemia, SLL, and MCL

Epratuzumab: an anti-CD22 monoclonal antibody for previously untreated FL and NHL

Isatuximab: an anti-CD38 monoclonal antibody for MM

Mogamulizumab: an anti-CCR4 monoclonal antibody for cutaneous T-cell lymphoma

Tremelimumab: an anti-CTLA4 monoclonal antibody for MM

Checkpoint Inhibitors

Atezolizumab: an anti-programmed death-ligand 1 (anti-PD-L1) inhibitor for MM

Durvalumab: an anti-PD-L1 inhibitor for MM

TTI-621: a CD47-targeting recombinant fusion protein for DLBCL

Antibody Drug Conjugates (ADC)

AGS67E: an anti-CD37 ADC for NHL

GSK2857916: an anti B-cell maturation agent (BCMA) monoclonal ADC for MM

Polatuzumab vedotin: an anti-CD79b ADC for DLBCL and FL

SGN-CD352A: an anti-CD352 ADC for MM

SGN-CD48A: an anti-CD48 ADC for MM

T-Cell Therapy

ACTR087: an autologous T-cell product for MM

bb2121: an anti-BCMA CAR T-cell therapy for MM

BI 836909: a bispecific T-cell engager (BiTE) targeting BCMA and CD3ɛ for MM

SINE XPO1 Antagonist

Selinexor: a first-in-class SINE XPO1 antagonist

Immunomodulatory Drugs

CC-220: a cereblon-binding immunomodulator